Rate My Professor Karin Jandeleit-Dahm

Professor Karin Jandeleit-Dahm serves as Deputy Head of the Department of Diabetes in the School of Translational Medicine at Monash University, holding the position of Professor (Research) in Diabetes. She leads the Diabetes and Kidney Disease research program, with a primary focus on elucidating the mechanisms underlying vascular complications of diabetes. Her work targets pathways involved in diabetic micro- and macrovascular diseases, including nephropathy and cardiovascular complications such as atherosclerosis. Key research themes include the role of NADPH oxidases, particularly Nox5, in generating oxidative stress; epigenetic modifications in endothelial-to-mesenchymal transition; and inflammasome inhibition in kidney disease. Her laboratory employs advanced animal models, human samples, and clinical validation to identify novel targets to prevent, treat, and reverse these complications.

Jandeleit-Dahm's contributions have established her as a leader in diabetic complications research, notably as the first to delineate the role of NADPH oxidases therein. She maintains international appointments as Professor of Medicine at the University of Hannover, Leibniz Chair for Diabetes Research at the University of Dusseldorf since 2019, and honorary affiliation at Maastricht University. With over 170 publications in premier journals like Circulation, Diabetes, Diabetologia, and the Journal of the American Society of Nephrology, she boasts an h-index of 56 and more than 10,000 citations. Selected works include "Nox1 plays a key role in diabetes accelerated atherosclerosis" (Circulation, 2013) and studies on Nox5 in diabetic nephropathy featured on the front cover of Diabetes (2017). Awards include Fellowship of the Australian Academy of Health and Medical Sciences (2018), Hans Christian Hagedorn Award (2022), and Kellion Award (2023). She serves on editorial boards for Diabetologia (over eight years), Clinical Science, PLOS One, and the Journal of Molecular Medicine; was past president of the Australian Atherosclerosis Society; and has delivered more than 40 international keynote lectures in the last five years. As chief investigator on NHMRC project grants and a multi-site JDRF/ARC-funded clinical trial for Nox inhibitors in type 1 diabetic nephropathy recruiting at 15 international sites, her impact spans from bench to bedside. She has supervised over 20 Honours students and five PhD students to completion.